Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
about
Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapyActivation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectorsOncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future PerspectivesHow Informative is the Immune Response Against Surrogate Tumor Antigens to Assess Antitumor Immunity?The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor controlInterference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseUsing virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site.Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent.Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.Cytokine conditioning enhances systemic delivery and therapy of an oncolytic virus.Deciphering the Multifaceted Relationship between Oncolytic Viruses and Natural Killer CellsORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic.Reporter gene imaging identifies intratumoral infection voids as a critical barrier to systemic oncolytic virus efficacy.The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated miceNK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytesOncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.Locoregional intravascular viral therapy of cancer: precision guidance for Paris's arrow?Glioma virus therapies between bench and bedside.Oncolytic vaccines.Evaluation of the oncolytic potential of R2B Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620).Immune System, Friend or Foe of Oncolytic Virotherapy?Measles virus causes immunogenic cell death in human melanoma.Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideNon-replicating rhabdovirus-derived particles (NRRPs) eradicate acute leukemia by direct cytolysis and induction of antitumor immunity.Activating Peripheral Innate Immunity Enables Safe and Effective Oncolytic Virotherapy in the Brain.Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy.Vanadium: A Panacea for Resistance to Oncolytic Immunotherapy?The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma.Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil".
P2860
Q28083766-29D4F7DB-C378-4968-B572-E69CD2687142Q28744029-1534ED26-7AED-4EAF-9E93-FD3578B1A6CDQ33679505-C7FE3968-F3C7-49B3-AE70-25A1E847451CQ33710433-54B36211-3328-4D0F-8FC4-8FD7EF8CC912Q33724224-6FA5A744-5113-4748-BAA8-E7AA7ED83F8CQ33832148-DC862DD7-9A7E-4FFB-B951-EAAECB985E9CQ33870670-0C29326B-B112-4A24-8350-33117E28FB9BQ34198856-692726BC-E481-4CBA-B9E3-B1B62F90CE2EQ34473352-42489562-9DF9-4EA3-8463-0EEB84556D93Q35212733-FE667D32-24C3-4532-93A4-9A26EF10B843Q35275179-D15E564D-8DE7-4B56-964E-6D3F6ABB7D73Q35531563-DF3065A3-CCC5-4696-93FB-AEE7D460FA5EQ35575688-953B0CC9-9E3F-47AE-A37F-BC4DEC0283ECQ35596563-F577CEED-5DD3-4B31-A486-495EF848C726Q35687743-E1488DDA-E5C7-4065-A2C2-53722518D45CQ36014043-095C5861-E6CE-475B-94DF-0D204FA93B28Q36664219-4D6A8EE3-D92E-48FD-92EA-19FEFB53B461Q36673729-1225188A-8923-429E-9304-3E2109B11C8CQ36890816-09D4464E-7A80-4850-B37F-D55FF100BA3DQ36911654-9AFC49AF-9C25-4961-B661-6803C5EE9B16Q37123143-DF5115B6-E87E-44B8-8EEA-64F0461FB69BQ37513298-05DE4A42-41FB-4515-A1A2-9E2DA92D7A84Q37580510-6DDE58AA-80E0-4E58-A319-D851F5D29AD0Q38152474-0B215D50-9879-454D-89D8-A569D2861EDFQ38701351-9BA6C81E-000F-4CDD-9334-1D0D2D9B6CC9Q39355854-64DAB548-6515-4B66-949B-7D4F3126AB48Q39428453-1552ADFD-2836-4B75-A6F1-C3A81753FCBDQ39473679-4D23B845-2C9B-4EB1-B61C-C8772E03B852Q39588655-017A4061-BA3D-44F0-B782-182FD6625B06Q41875584-DD7F26D4-28D9-43FF-B999-AED16E34E3FCQ41879725-19C7F6B1-D792-4D00-8B3B-032772F936DCQ42157100-5B05F944-7D42-4191-8DB1-D595F0114CC5Q42283940-9B7FA254-E2FC-4BD9-A8CB-A47B03325CC6Q42795549-A56E2816-8BCE-45A9-A4C0-EF7643DD9AF5Q48893820-4D73B169-E288-4C39-B55C-CA1172E357F4Q49715030-C69A6B97-4535-401D-8803-47129F70B76FQ52677347-5D13F0BC-A041-4274-96EC-4018786F3586Q52686341-9CC427BF-7E52-4068-9661-8F6FCD25CA9BQ52688581-C8466D81-5885-4477-B14E-5663C261AD0CQ54378300-2745E30C-2C40-4A4E-9EAF-0B4213E1E5B7
P2860
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@en
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@en-gb
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@nl
type
label
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@en
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@en-gb
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@nl
prefLabel
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@en
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@en-gb
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@nl
P2093
P2860
P356
P1154
2-s2.0-76749162295
P1433
P1476
Single-cycle viral gene expres ...... r VSV therapy of B16 melanoma.
@en
P2093
J Thompson
P Wongthida
P2860
P2888
P304
P356
10.1038/GT.2009.161
P5530
P577
2009-12-17T00:00:00Z
P5875
P6179
1047696154